Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 7/20 | 0.44 |
| ▸ | JAK2 | O60674 | 6/20 | 0.44 |
| ▸ | JAK3 | P52333 | 6/20 | 0.44 |
| ▸ | ABL1 | P00519 | 4/20 | 0.44 |
| ▸ | TYK2 | P29597 | 4/20 | 0.44 |
| ▸ | STAT3 | P40763 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 10/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 10/20 | 0.42 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2355597 | 1.00 | JAK1 (0.44) | JAK1JAK2JAK3ABL1TYK2 | |
| SCHEMBL4410398 | 0.93 | CCNE1 (0.49) | JAK1JAK2JAK3ABL1TYK2 | |
| SCHEMBL2358705 | 0.93 | CCNE1 (0.49) | JAK1JAK2JAK3ABL1TYK2 | |
| SCHEMBL3310399 | 0.88 | ABL1 (0.51) | JAK1JAK2JAK3ABL1TYK2 | |
| SCHEMBL17451314 | 0.86 | ABL1 (0.53) | JAK1JAK2JAK3ABL1TYK2 | |
| SCHEMBL3310920 | 0.85 | JAK2 (0.52) | JAK1JAK2JAK3ABL1TYK2 | |
| SCHEMBL2357196 | 0.84 | JAK2 (0.50) | JAK1JAK2JAK3ABL1TYK2 | |
| SCHEMBL17451310 | 0.82 | JAK2 (0.43) | JAK1JAK2JAK3ABL1TYK2 | |
| SCHEMBL3311712 | 0.82 | ABL1 (0.49) | JAK1JAK2JAK3ABL1TYK2 | |
| SCHEMBL3309501 | 0.82 | ABL1 (0.47) | JAK1JAK2JAK3ABL1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220068-B1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2220068-B1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8309718-B2 | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309718-B2 | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309718-B2 | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009064835-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.